Harpoon Therapeutics, Inc. has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the Company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.
“We are pleased to enter into this clinical supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform,” stated Julie Eastland, President and CEO, Harpoon Therapeutics. “We are pleased with the compelling profile emerging in our monotherapy study and we plan to initiate combination trials in multiple lines of therapy for patients with small cell lung cancer, a disease with unmet medical need.”
Under this agreement, Harpoon is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!